15 January 2019 - - US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has priced of an underwritten public offering of 5m shares of its common stock at a public offering price of USD 77.50 per share.

The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately USD 387.5m.

The offering is expected to close on or about January 17, 2019, subject to the satisfaction of customary closing conditions. In addition, Alnylam has granted the underwriter a 30-day option to purchase up to an additional 750,000 shares of its common stock solely to cover over-allotments.

All of the shares in the offering are to be sold by Alnylam.

Barclays Capital Inc. is acting as sole book-running manager for the offering.

Alnylam said it plans to use the net proceeds from this offering for general corporate purposes, including advancing the ongoing commercialisation of Onpattro (patisiran) in the United States and Europe and, assuming favorable regulatory reviews, the potential expansion into additional countries, development efforts directed towards the potential expansion of the Onpattro label in the United States, continuing to advance its late stage clinical pipeline and preparing for the potential global launch of several additional products, continuing investment in its early stage pipeline, including its CNS and ocular programmes, clinical trial costs and other research and development expenses, continued growth of its manufacturing, quality, commercial and medical affairs capabilities to support its commercialisation efforts, potential acquisitions, investments or licenses in businesses, products or technologies that are complementary to Alnylam's business, working capital, capital expenditures and general and administrative expenses.

Alnylam (NASDAQ: ALNY) is engaged in the translation of RNA interference into a new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system /ocular diseases.

Founded in 2002, Alnylam's Onpattro (patisiran) lipid complex injection, available in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, is its first US FDA-approved RNAi therapeutic.

In the EU, Onpattro is approved for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of investigational medicines, including three product candidates that are in late-stage development.

Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1,000 people worldwide and is headquartered in Cambridge, MA.